UPDATE: Bank of America Upgrades ResMed on Multiple Positive Factors

In a report published Monday, Bank of America analyst Matthew Prior upgraded the rating on ResMed (NYSE: RMD ) from Neutral to Buy, and raised the price target from $5.07 to $5.65. In the report, Bank of America noted, “We upgrade RMD to Buy with expectation of a near term